Edwards Lifesciences Corp (EW) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Total Cash From Operating Activities Chart for Edwards Lifesciences Corp
Edwards Lifesciences Corp (EW) operating cash flow for FY2025 was USD 1.6B, a 194.2% change from FY2024. Edwards Lifesciences Corp's operating cash flow grew from USD 176.0M in 1999 to USD 1.6B in 2025 (806.4% over 26 years). Operating cash flow compound annual growth rate: 5-year CAGR of 8.6%, 10-year CAGR of 11.2%, 20-year CAGR of 13.1%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $51.43B
- Implied Share Price
- $89.32
- Enterprise Value
- $48.04B
- Revenue (TTM)
- $6.51B
- EBITDA
- $2.00B
- Profit Margin
- 15.43%
- Trailing P/E
- 53.17
- Forward P/E
- 29.85
- Price/Book (MRQ)
- 4.86
- Price/Sales (TTM)
- 7.91
- EV/EBITDA
- 29.08
- EV/Revenue
- 7.38
- Dividend Yield
- —
- Book Value
- $17.90
- Free Cash Flow (FY2025)
- $1.33B
- Free Cash Flow Yield
- 2.60%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.